Company Description
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.
It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1.
It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F.
Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V.
and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000.
Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
| Country | United States |
| Founded | 1994 |
| IPO Date | Apr 7, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,147 |
| CEO | Michael Morrissey |
Contact Details
Address: 1851 Harbor Bay Parkway Alameda, California 94502 United States | |
| Phone | 650 837 7000 |
| Website | exelixis.com |
Stock Details
| Ticker Symbol | EXEL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000939767 |
| CUSIP Number | 30161Q104 |
| ISIN Number | US30161Q1040 |
| Employer ID | 04-3257395 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael M. Morrissey Ph.D. | Chief Executive Officer, President and Director |
| Dr. Stelios Papadopoulos Ph.D. | Co-Founder and Independent Chair of the Board |
| Christopher J. Senner | Executive Vice President and Chief Financial Officer |
| Dr. Dana T. Aftab Ph.D. | Executive Vice President of Discovery and Translational Research and Chief Scientific Officer |
| Jeffrey J. Hessekiel J.D. | Executive Vice President and General Counsel |
| Dr. Amy C. Peterson M.D. | Executive Vice President of Product Development and Medical Affairs and Chief Medical Officer |
| Susan T. Hubbard | Executive Vice President of Public Affairs and Investor Relations |
| Dr. Anne Champsaur M.D. | Senior Vice President of Drug Safety |
| Patrick Joseph Haley M.B.A. | Executive Vice President of Commercial |
| Dr. Stefan Krauss Ph.D. | Vice President and Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 28, 2025 | 10-Q | Quarterly Report |
| Jul 28, 2025 | 8-K | Current Report |
| Jun 3, 2025 | 144 | Filing |
| Jun 2, 2025 | 144 | Filing |
| Jun 2, 2025 | 8-K | Current Report |
| May 21, 2025 | 144 | Filing |
| May 20, 2025 | SCHEDULE 13D/A | Filing |
| May 20, 2025 | 144 | Filing |
| May 16, 2025 | 144 | Filing |
| May 16, 2025 | 144 | Filing |